All In Biotech

Drug Trial Radar · NCT00620451

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With Larazotide Acetate (AT-1001)

Last checked: Nov 19, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Feb 2008

Primary completion

Jul 2009

Study completion Dec 2009

Sponsor

Lead sponsor
9 Meters Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Feb 21, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.

Conditions

  • Celiac Disease

Interventions

  • larazotide acetateDrug

    gelatin capsule

  • placeboDrug

    gelatin capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the efficacy of larazotide acetate in inducing remission in subjects with active celiac diseaseTime frame: duodeno-jejunal biopsies were performed at Baseline and Day 56

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Study Site

    Orange, California

  • Study Site

    San Francisco, California

  • Study Site

    Torrington, Connecticut

  • Study Site

    Jacksonville, Florida

  • Study Site

    Topeka, Kansas

  • Study Site

    Lexington, Kentucky

  • Study Site

    Hagerstown, Maryland

  • Study Site

    Silver Spring, Maryland

  • Study Site

    Chesterfield, Michigan

  • Study Site

    Troy, Michigan

  • Study Site

    Rochester, Minnesota

  • Study Site

    Asheville, North Carolina

  • Study Site

    Harrisburg, North Carolina

  • Study Site

    Gallipolis, Ohio

  • Study Site

    Paoli, Pennsylvania

  • Study Site

    Philadelphia, Pennsylvania

  • Study Site

    Pittsburgh, Pennsylvania

  • Study Site

    Sioux Falls, South Dakota

  • Study Site

    Franklin, Tennessee

  • Study Site

    Houston, Texas

  • Study Site

    Edmonton, Alberta, Canada

  • Study Site

    Abbotsford British Columbia, British Columbia, Canada

  • Study Site

    Kelowna, British Columbia, Canada

  • Study Site

    Richmond Hill, Ontario, Canada

  • Study Site

    Barcelona, Spain

  • Study Site

    Huesca, Spain

  • Study Site

    León, Spain

  • Study Site

    Madrid, Spain

  • Study Site

    Madrid, Spain

  • Study site

    Madrid, Spain

  • Study Site

    Reus, Spain

  • Study Site

    Valladolid, Spain

  • Study Site

    Palma, Mallorca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.